Peptide vaccine design against glioblastoma by applying immunoinformatics approach
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.113219 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Mahsa Mohammadi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Computer Science, Faculty of Mathematics, Statistics, and Computer Science, University of Tabriz, Tabriz, Iran. Hauptthemen laut MEDLINE: Glioblastoma, Vaccines, Subunit, Cancer Vaccines, Computational Biology. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben.
Abstract (Originalsprache)
Brain tumors are considered to be one of the most fatal forms of cancer owing to their highly aggressive attributes, diverse characteristics, and notably low rate of survival. Among these tumors, glioblastoma stands out as the prevalent and perilous variant Despite the present advancements in surgical procedures, pharmacological treatment, and radiation therapy, the overall prognosis remains notably unfavorable, as merely 4.3 % of individuals manage to attain a five-year survival rate; For this reason, it has emerged as a challenge for cancer researchers. Therefore, among several immunotherapy methods, using peptide-based vaccines for cancer treatment is considered promising due to their ability to generate a focused immune response with minimal damage. This study endeavors to devise a multi-epitope vaccine utilizing an immunoinformatics methodology to address the challenge posed by glioblastoma disease. Through this approach, it is anticipated that the duration and expenses associated with vaccine manufacturing can be diminished, while simultaneously enhancing the characteristics of the vaccine. The target gene in this research is ITGA5, which was achieved through TCGA analysis by targeting the PI3K-Akt pathway as a significant association with patient survival. Subsequently, the suitable epitopes of T and B cells were selected through various immunoinformatics tools by analyzing their sequence. Then, nine epitopes were merged with GM-CSF as an adjuvant to enhance immunogenicity. The outcomes encompass molecular docking, molecular dynamics (MD) simulation, simulation of the immune response, prognosis and confirmation of the secondary and tertiary structure, Chemical and physical characteristics, toxicity, as well as antigenicity and allergenicity of the potential vaccine candidate against glioblastoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Computer Science, Faculty of Mathematics, Statistics, and Computer Science, University of Tabriz, Tabriz, Iran.
- Department of Computer Science, Faculty of Mathematics, Statistics, and Computer Science, University of Tabriz, Tabriz, Iran. Electronic address: razmara@tabrizu.ac.ir.
- Physiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.
- Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran.
- Bioinformatics Research Group, Faculty of Science, Universiti Teknologi Malaysia, Johor Bahru, Malaysia.
Zitieren
APA
Mohammadi, M., Razmara, J., Hadizadeh, M., Parvizpour, S., & Shahir Shamsir, M. (2024). Peptide vaccine design against glioblastoma by applying immunoinformatics approach. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.113219
Vancouver
Mohammadi M, Razmara J, Hadizadeh M, Parvizpour S, Shahir Shamsir M. Peptide vaccine design against glioblastoma by applying immunoinformatics approach. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.113219
BibTeX
@article{Mohammadi2024,
author = {Mohammadi, Mahsa and Razmara, Jafar and Hadizadeh, Morteza and Parvizpour, Sepideh and Shahir Shamsir, Mohd},
title = {Peptide vaccine design against glioblastoma by applying immunoinformatics approach},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.113219}
}
EUVIMED